Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Product |
Terms/Details (Date) |
| |||
Altus Pharmaceuticals Inc. (ALTU) |
Lonza Group Ltd. (Switzerland) |
Deal for the commercial manufacture of Altus' ALTU-135 drug substances at Lonza's facility the Czech Republic |
The oral enzyme replacement therapy for patients with pancreatic insufficiency is entering Phase III trials; terms of the deal were not disclosed (11/17) |
| |||
Ambrilia Biopharma Inc. (Canada; TSX:AMB) |
Various companies |
Ambrilia entered deals for European sales of its sustained-release formulation of Octreotide for acromegaly |
Archimedes Pharma Ltd. will distribute the product in the UK; Gerolymatos Group of Cos. in Greece, Turkey and other countries; Pharmis in Portugal and Brazil; and Kwidza Pharma GmbH in Austria (12/5) |
| |||
BioServe Biotechnologies* |
Merck Specialties Private Ltd. (Indian subsidiary of Merck KGaA; Germany) |
MSPL will market and distribute BioServe's genomic products and services in India |
The plan is to extend the distribution deal across Asia in 2007; terms were not disclosed (1/9) |
| |||
Celgene Corp. (CELG) |
Siegfried Ltd. (Switzerland) |
Celgene acquired an active pharmaceutical ingredient manufacturing facility |
Celgene is paying $46.5M in cash, with an initial payment of $12.5M; the facility initially will be used to produce Revlimid (12/11) |
| |||
Crucell NV (the Netherlands; CRXL) |
Abbott Laboratories |
Non-exclusive STAR research license agreement for the production of monoclonal antibodies |
Abbott would evaluate Crucell's STAR technology for generating cell lines for manufacture of biopharmaceuticals (1/31) |
| |||
DiaKine Therapeutics Inc.* |
AdPharma Inc. |
Agreement to develop drugs aimed at reversing diabetes with the contract research firm AdPharma |
Terms call for AdPharma to provide drug development services at a discount in exchange for an undisclosed number of DiaKine's common shares; AdPharma made an investment in DiaKine's convertible note (1/31) |
| |||
DiaKine Therapeutics Inc.* |
Mediatech Inc. |
Deal to market DiaKine's Lisofylline to islet cell transplant centers worldwide |
The product is designed to block autoimmune damage to insulin-producing cells; resulting revenues would be shared (1/10) |
| |||
Durect Corp. (DRRX) |
Hospira Worldwide Inc. |
Manufacturing and supply agreement for POSIDUR, Durect's postsurgical pain management investigational drug |
POSIDUR is a long-acting local anesthetic that is intended to be injected during surgery; Hospira will provide clinical and commercial supplies on a worldwide basis (1/29) |
| |||
Gentium SpA (Italy; GENT) |
Crinos SpA (Italy) |
Gentium acquired Italian marketing authorizations for Defibrotide, which is being developed for veno-occulsive disease and other indications |
Gentium is paying €8M up front and |8M more over two years; Crinos agreed to waive its right of first refusal to market the product in Europe for other indications; Crinos would get royalties on sales (1/3) |
| |||
Helix BioPharma Corp. (Canada; TSX:HBP) |
BioVectra (division of Diagnostic Chemicals Ltd.) |
Deal under which BioVectra will manufacture L-DOS47 bulk drug product for human clinical testing |
The preclinical product is a targeted agent for treating adenocarcinoma of the lung; terms of the deal were not disclosed (1/5) |
| |||
Pharmaxis (Australia; PXSL) |
Aldo-Union SA (Spain) |
Aldo-Union will market and distribute Pharmaxis' asthma diagnostic and management tool, Aridol, in Spain |
Specific terms were not disclosed (1/22) |
| |||
Transgenomic Inc. (TBIO) |
ARUP Laboratories |
Strategic relationship in which Transgenomic will provide reference laboratory services to ARUP for the analysis of patient samples for mitochondrial DNA mutations, and mutations for other disorders |
Transgenomic has developed expertise in analyzing the whole mitochondrial genome, and proprietary tools have allowed the company to detect mutations in samples with less than 5% of mutated DNA (1/31) |
| |||
Trubion Pharmaceuticals Inc. (TRBN) |
Laureate Pharma Inc. |
Agreement to produce TRU-016, a protein for non-Hodgkin's lymphoma |
Financial terms were not disclosed (1/30) |
| |||
Unigene Laboratories Inc. (OTC BB:UGNE) |
Novartis AG (Switzerland) |
Supply agreement for the bulk peptide necessary to support Novartis' osteoporosis drug development program |
Unigene will use its manufacturing technology to develop an FDA-compliant process for the peptide, and Novartis will have the chance to purchase additional quantities as necessary (1/29) |
| |||
Vion Pharmaceuticals Inc. (VION) |
Ben Venue Laboratories (unit of Boehringer Ingelheim GmbH; Germany) |
Deal under which Ben Venue will manufacture Vion's cancer drug Cloretazine (VNP40101M) |
The alkylating agent is in Phase II and III trials; terms of the deal were not disclosed (12/13) |
| |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. |